POMPANO BEACH, Fla.--(BUSINESS WIRE)--StimGuard, a privately-held, pre-commercial medical device company, today announced it is commencing a head-to-head study for its Chronic Affarent Nerve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback